Internet Content & Information
Compare Stocks
5 / 10Stock Comparison
UPXI vs SKIN vs HIMS vs AMZN vs SHOP
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Medical - Equipment & Services
Specialty Retail
Software - Application
UPXI vs SKIN vs HIMS vs AMZN vs SHOP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Internet Content & Information | Household & Personal Products | Medical - Equipment & Services | Specialty Retail | Software - Application |
| Market Cap | $11M | $118M | $6.63B | $2.92T | $145.00B |
| Revenue (TTM) | $25M | $296M | $2.35B | $742.78B | $12.37B |
| Net Income (TTM) | $-123M | $-6M | $128M | $90.80B | $1.33B |
| Gross Margin | 80.7% | 64.9% | 69.7% | 50.6% | 48.0% |
| Operating Margin | -470.1% | -3.6% | 4.6% | 11.5% | 13.3% |
| Forward P/E | — | — | 51.5x | 34.8x | 60.9x |
| Total Debt | $28M | $379M | $1.12B | $152.99B | $188M |
| Cash & Equiv. | $3M | $233M | $229M | $86.81B | $1.53B |
UPXI vs SKIN vs HIMS vs AMZN vs SHOP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Upexi, Inc. (UPXI) | 100 | 1.1 | -98.9% |
| The Beauty Health C… (SKIN) | 100 | 5.4 | -94.6% |
| Hims & Hers Health,… (HIMS) | 100 | 235.7 | +135.7% |
| Amazon.com, Inc. (AMZN) | 100 | 157.6 | +57.6% |
| Shopify Inc. (SHOP) | 100 | 76.5 | -23.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UPXI vs SKIN vs HIMS vs AMZN vs SHOP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UPXI plays a supporting role in this comparison — it may shine differently against other peers.
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
HIMS is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- Beta 2.40, current ratio 1.90x
- 59.0% revenue growth vs UPXI's -39.2%
AMZN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.51
- Lower volatility, beta 1.51, Low D/E 37.2%, current ratio 1.05x
- PEG 1.24 vs SHOP's 2.08
- Lower P/E (34.8x vs 60.9x), PEG 1.24 vs 2.08
SHOP is the clearest fit if your priority is long-term compounding.
- 41.2% 10Y total return vs AMZN's 7.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs UPXI's -39.2% | |
| Value | Lower P/E (34.8x vs 60.9x), PEG 1.24 vs 2.08 | |
| Quality / Margins | 12.2% margin vs UPXI's -496.9% | |
| Stability / Safety | Beta 1.51 vs UPXI's 3.63 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +43.7% vs UPXI's -88.3% | |
| Efficiency (ROA) | 11.5% ROA vs UPXI's -45.3%, ROIC 14.7% vs -14.0% |
UPXI vs SKIN vs HIMS vs AMZN vs SHOP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
UPXI vs SKIN vs HIMS vs AMZN vs SHOP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMZN leads in 3 of 6 categories
UPXI leads 0 • SKIN leads 0 • HIMS leads 0 • SHOP leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — UPXI and AMZN and SHOP each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMZN is the larger business by revenue, generating $742.8B annually — 30021.9x UPXI's $25M. AMZN is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to UPXI's -5.0%. On growth, UPXI holds the edge at +101.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $25M | $296M | $2.3B | $742.8B | $12.4B |
| EBITDAEarnings before interest/tax | -$116M | $9M | $164M | $155.9B | $1.7B |
| Net IncomeAfter-tax profit | -$123M | -$6M | $128M | $90.8B | $1.3B |
| Free Cash FlowCash after capex | -$18M | $29M | $73M | -$2.5B | $2.1B |
| Gross MarginGross profit ÷ Revenue | +80.7% | +64.9% | +69.7% | +50.6% | +48.0% |
| Operating MarginEBIT ÷ Revenue | -4.7% | -3.6% | +4.6% | +11.5% | +13.3% |
| Net MarginNet income ÷ Revenue | -5.0% | -2.0% | +5.5% | +12.2% | +10.8% |
| FCF MarginFCF ÷ Revenue | -71.7% | +9.8% | +3.1% | -0.3% | +17.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +101.0% | -6.7% | +28.4% | +16.6% | +34.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -137.1% | +38.0% | -27.3% | +74.8% | +15.1% |
Valuation Metrics
Evenly matched — SKIN and AMZN each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 37.8x trailing earnings, AMZN trades at a 68% valuation discount to SHOP's 118.9x P/E. Adjusting for growth (PEG ratio), AMZN offers better value at 1.35x vs SHOP's 4.06x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $11M | $118M | $6.6B | $2.92T | $145.0B |
| Enterprise ValueMkt cap + debt − cash | $35M | $264M | $7.5B | $2.98T | $143.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.77x | -5.69x | 50.32x | 37.82x | 118.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 51.51x | 34.77x | 60.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.35x | 4.06x |
| EV / EBITDAEnterprise value multiple | — | 7331.15x | 42.68x | 20.47x | 95.83x |
| Price / SalesMarket cap ÷ Revenue | 0.67x | 0.39x | 2.82x | 4.07x | 12.55x |
| Price / BookPrice ÷ Book value/share | 0.12x | 2.02x | 12.25x | 7.14x | 10.82x |
| Price / FCFMarket cap ÷ FCF | — | 3.17x | 89.61x | 378.98x | 72.25x |
Profitability & Efficiency
AMZN leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-3 for UPXI. SHOP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.5% | -9.4% | +23.7% | +23.3% | +10.5% |
| ROA (TTM)Return on assets | -45.3% | -1.2% | +6.0% | +11.5% | +9.0% |
| ROICReturn on invested capital | -14.0% | -6.8% | +10.7% | +14.7% | +9.4% |
| ROCEReturn on capital employed | -24.5% | -4.5% | +10.9% | +15.3% | +11.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 4 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.31x | 6.20x | 2.07x | 0.37x | 0.01x |
| Net DebtTotal debt minus cash | $25M | $146M | $892M | $66.2B | -$1.3B |
| Cash & Equiv.Liquid assets | $3M | $233M | $229M | $86.8B | $1.5B |
| Total DebtShort + long-term debt | $28M | $379M | $1.1B | $153.0B | $188M |
| Interest CoverageEBIT ÷ Interest expense | -10.65x | 0.81x | — | 39.96x | — |
Total Returns (Dividends Reinvested)
AMZN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $120 for UPXI. Over the past 12 months, AMZN leads with a +43.7% total return vs UPXI's -88.3%. The 3-year compound annual growth rate (CAGR) favors AMZN at 36.8% vs UPXI's -74.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -29.8% | -35.0% | -23.2% | +19.7% | -28.9% |
| 1-Year ReturnPast 12 months | -88.3% | -35.9% | -51.0% | +43.7% | +18.2% |
| 3-Year ReturnCumulative with dividends | -98.4% | -91.7% | +116.6% | +156.2% | +73.6% |
| 5-Year ReturnCumulative with dividends | -98.8% | -92.9% | +137.6% | +64.8% | +0.8% |
| 10-Year ReturnCumulative with dividends | -98.8% | -91.6% | +161.9% | +697.8% | +4123.0% |
| CAGR (3Y)Annualised 3-year return | -74.8% | -56.4% | +29.4% | +36.8% | +20.2% |
Risk & Volatility
AMZN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMZN is the less volatile stock with a 1.51 beta — it tends to amplify market swings less than UPXI's 3.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMZN currently trades 97.3% from its 52-week high vs UPXI's 8.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.63x | 2.00x | 2.40x | 1.51x | 2.64x |
| 52-Week HighHighest price in past year | $15.50 | $2.69 | $70.43 | $278.56 | $182.19 |
| 52-Week LowLowest price in past year | $0.54 | $0.76 | $13.74 | $185.01 | $88.14 |
| % of 52W HighCurrent price vs 52-week peak | +8.6% | +33.8% | +36.4% | +97.3% | +61.3% |
| RSI (14)Momentum oscillator 0–100 | 59.1 | 52.1 | 54.5 | 81.1 | 34.7 |
| Avg Volume (50D)Average daily shares traded | 5.0M | 760K | 34.9M | 45.5M | 8.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SKIN as "Hold", HIMS as "Hold", AMZN as "Buy", SHOP as "Buy". Consensus price targets imply 47.4% upside for SHOP (target: $165) vs 13.1% for AMZN (target: $307).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $1.30 | $29.67 | $306.77 | $164.75 |
| # AnalystsCovering analysts | — | 13 | 19 | 94 | 63 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% | 0.0% |
AMZN leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 2 categories are tied.
UPXI vs SKIN vs HIMS vs AMZN vs SHOP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is UPXI or SKIN or HIMS or AMZN or SHOP a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -39. 2% for Upexi, Inc. (UPXI). Amazon. com, Inc. (AMZN) offers the better valuation at 37. 8x trailing P/E (34. 8x forward), making it the more compelling value choice. Analysts rate Amazon. com, Inc. (AMZN) a "Buy" — based on 94 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UPXI or SKIN or HIMS or AMZN or SHOP?
On trailing P/E, Amazon.
com, Inc. (AMZN) is the cheapest at 37. 8x versus Shopify Inc. at 118. 9x. On forward P/E, Amazon. com, Inc. is actually cheaper at 34. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Amazon. com, Inc. wins at 1. 24x versus Shopify Inc. 's 2. 08x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — UPXI or SKIN or HIMS or AMZN or SHOP?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -98. 8% for Upexi, Inc. (UPXI). Over 10 years, the gap is even starker: SHOP returned +41. 2% versus UPXI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UPXI or SKIN or HIMS or AMZN or SHOP?
By beta (market sensitivity over 5 years), Amazon.
com, Inc. (AMZN) is the lower-risk stock at 1. 51β versus Upexi, Inc. 's 3. 63β — meaning UPXI is approximately 140% more volatile than AMZN relative to the S&P 500. On balance sheet safety, Shopify Inc. (SHOP) carries a lower debt/equity ratio of 1% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — UPXI or SKIN or HIMS or AMZN or SHOP?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -39. 2% for Upexi, Inc. (UPXI). On earnings-per-share growth, the picture is similar: Upexi, Inc. grew EPS 92. 8% year-over-year, compared to -39. 4% for Shopify Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UPXI or SKIN or HIMS or AMZN or SHOP?
Amazon.
com, Inc. (AMZN) is the more profitable company, earning 10. 8% net margin versus -86. 5% for Upexi, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHOP leads at 12. 7% versus -79. 1% for UPXI. At the gross margin level — before operating expenses — UPXI leads at 68. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is UPXI or SKIN or HIMS or AMZN or SHOP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Amazon. com, Inc. (AMZN) is the more undervalued stock at a PEG of 1. 24x versus Shopify Inc. 's 2. 08x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Amazon. com, Inc. (AMZN) trades at 34. 8x forward P/E versus 60. 9x for Shopify Inc. — 26. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SHOP: 47. 4% to $164. 75.
08Which pays a better dividend — UPXI or SKIN or HIMS or AMZN or SHOP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is UPXI or SKIN or HIMS or AMZN or SHOP better for a retirement portfolio?
For long-horizon retirement investors, Amazon.
com, Inc. (AMZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+697. 8% 10Y return). Upexi, Inc. (UPXI) carries a higher beta of 3. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMZN: +697. 8%, UPXI: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between UPXI and SKIN and HIMS and AMZN and SHOP?
These companies operate in different sectors (UPXI (Communication Services) and SKIN (Consumer Defensive) and HIMS (Healthcare) and AMZN (Consumer Cyclical) and SHOP (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: UPXI is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; AMZN is a mega-cap quality compounder stock; SHOP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 50%
- Gross Margin > 48%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.